Blueprint Medicines (NASDAQ: BPMC) Corporation, a commercial-stage biotechnology company with a market capitalization of $8.27 billion, has been making significant strides in the pharmaceutical ...

In conclusion, Blueprint Medicines stands at a pivotal juncture with its recent acquisition by Sanofi and the continued success of Ayvakit. The stock has demonstrated strong momentum, with a 37.31% ...

Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 potential. Click for more on SNY and BPMC.

Sanofi has agreed to acquire Blueprint Medicines for $9.1 billion, expanding its footprint in rare immunological diseases. The purchase includes a 27% premium per share and could total nearly $9.5 ...

Sanofi agreed to acquire Blueprint Medicines, a Cambridge, Mass.-based biotech focused on rare immunology diseases, for $9.1 billion in cash and up to $400 million in earnouts. Why it matters ...

On June 3, Citizens JMP analyst Reni Benjamin downgraded Blueprint Medicines Corporation (NASDAQ: BPMC) to Market Perform from Outperform without a price target. The rating update followed Sanofi ...

On June 3, Stephens & Co. analyst Sudan Loganathan downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Equal Weight from Overweight, slashing the price target to $135 from $150.

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

CAMBRIDGE, Mass., June 12, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting over a decade of collaboration with clinical experts ...

The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine development by leveraging local health-tech ecosystems and research ...